The three-year signature initiative is designed to make learning about health and disease engaging, accessible, and exciting for students in grades 6-8, primarily in under-resourced schools across the country.
The programme will kick off with a Virtual Field Trip to AstraZeneca's Gaithersburg, MD, research laboratories, which will premiere on Tuesday, October 8, 2019 at 1:00 p.m. ET / 10:00 a.m. PT.
The programme, Generation Health: How Science Powers Us, will provide students first-hand access to the technology and scientists working to create medical breakthroughs for the world's most pressing health problems. Educators, parents and students are invited to register here.
Participants are encouraged to join a live Twitter chat during the premiere by submitting questions and sending pictures using #GenerationHealthVFT.
Generation Health: How Science Powers Us will provide hands-on, standards-aligned STEM learning activities where students investigate both preventative measures and innovative solutions to key health concerns in the areas of oncology, cardiovascular, and respiratory disease.
The programme will also offer resources for employee engagement in the classroom.
As part of this program, Generation Health provides a suite of educational resources, including, Learning Undefeated's Drop Anywhere Labs, custom-outfitted STEM learning spaces built from modified shipping containers.
These light, easy-to-access and inexpensive labs provide a range of career and skills education for middle school students, as well as flexible in-classroom resources that empower teachers and enables them to serve up to four classes simultaneously.
NeuroSense Therapeutics completes safety evaluation of PrimeC in Alzheimer's Phase 2 study
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
PRISM BioLab partners with Talus Bioscience to address TF and PPI targets
Thryv Therapeutics reports positive Phase 1 results for THRV-1268